According to Matinas BioPharma's latest financial reports the company's current earnings are N/A. In 2023 the company made an earning of -โน1.99 Billion a decrease over its 2022 earnings that were of -โน1.82 Billion. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Year | Earnings | Change |
---|---|---|
2024 (TTM) | -โน1.77 Billion | -11.35% |
2023 | -โน1.99 Billion | 9.26% |
2022 | -โน1.82 Billion | -9.82% |
2021 | -โน2.02 Billion | 3.73% |
2020 | -โน1.95 Billion | 29.21% |
2019 | -โน1.51 Billion | 19.07% |
2018 | -โน1.27 Billion | -7.91% |
2017 | -โน1.38 Billion | 108.5% |
2016 | -โน0.66 Billion | -16.82% |
2015 | -โน0.8 Billion | -10.62% |
2014 | -โน0.89 Billion | 175.27% |
2013 | -โน0.33 Billion |